Look­ing for an ad­van­tage in the crowd­ed SMA space, Roche’s Genen­tech re­leas­es fresh Evrys­di da­ta

Roche has been look­ing for an edge in the SMA race, which so far has been dom­i­nat­ed by Bio­gen’s Spin­raza and No­var­tis’ Zol­gens­ma. And the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.